Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, Mampre D, Jackson C, Peterson J, et al. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol. 2020;147:297–307.
Sampetrean O, Saya H. Characteristics of glioma stem cells. Brain Tumor Pathol. 2013;30:209–14.
Schonberg DL, Lubelski D, Miller TE, Rich JN. Brain tumor stem cells: molecular characteristics and their impact on therapy. Mol Asp Med. 2014;39:82–101.
Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis. 2015;2:152–63.
Shen S-H, Yu N, Liu X-Y, Tan G-W, Wang Z-X. Gamma-glutamylcyclotransferase promotes the growth of human glioma cells by activating Notch-Akt signaling. Biochem Biophys Res Commun. 2016;471:616–20.
He Z, Wang S, Shao Y, Zhang J, Wu X, Chen Y, et al. Ras downstream effector GGCT alleviates oncogenic stress. iScience. 2019;19:256–66.
Oakley AJ, Coggan M, Board PG. Identification and characterization of gamma-glutamylamine cyclotransferase, an enzyme responsible for gamma-glutamyl-epsilon-lysine catabolism. J Biol Chem. 2010;285:9642–8.
Kageyama S, Ii H, Taniguchi K, Kubota S, Yoshida T, Isono T, et al. Mechanisms of tumor growth inhibition by depletion of γ-glutamylcyclotransferase (GGCT): a novel molecular target for anticancer therapy. Int J Mol Sci. 2018;19:2054.
Matsumura K, Nakata S, Taniguchi K, Ii H, Ashihara E, Kageyama S, et al. Depletion of γ-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation. BMC Cancer. 2016;16:748.
Taniguchi K, Matsumura K, Kageyama S, Ii H, Ashihara E, Chano T, et al. Prohibitin-2 is a novel regulator of p21WAF1/CIP1 induced by depletion of γ-glutamylcyclotransferase. Biochem Biophys Res Commun. 2018;496:218–24.
Taniguchi K, Ii H, Kageyama S, Takagi H, Chano T, Kawauchi A, et al. Depletion of gamma-glutamylcyclotransferase inhibits cancer cell growth by activating the AMPK-FOXO3a-p21 axis. Biochem Biophys Res Commun. 2019;517:238–43.
Taniguchi K, Matsumura K, Ii H, Kageyama S, Ashihara E, Chano T, et al. Depletion of gamma-glutamylcyclotransferase in cancer cells induces autophagy followed by cellular senescence. Am J Cancer Res. 2018;8:650–61.
Ii H, Yoshiya T, Nakata S, Taniguchi K, Hidaka K, Tsuda S, et al. A novel prodrug of a γ-glutamylcyclotransferase inhibitor suppresses cancer cell proliferation in vitro and inhibits tumor growth in a xenograft mouse model of prostate cancer. ChemMedChem. 2018;13:155–63.
Ii H, Nohara Y, Yoshiya T, Masuda S, Tsuda S, Oishi S, et al. Identification of U83836E as a γ-glutamylcyclotransferase inhibitor that suppresses MCF7 breast cancer xenograft growth. Biochem Biophys Res Commun. 2021;549:128–34.
Ii H, Kasahara Y, Yamaguma H, Kageyama S, Kawauchi A, Obika S, et al. Administration of Gapmer-type Antisense Oligonucleotides Targeting γ-Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts. Anticancer Res. 2022;42:1221–7.
Ohno Y, Hattori A, Ueda M, Kageyama S, Yoshiki T, Kakeya H. Multiple NF-Y-binding CCAAT boxes are essential for transcriptional regulation of the human C7orf24 gene, a novel tumor-associated gene. FEBS J. 2011;278:4088–99.
Meng Q, Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell. 2011;2:889–98.
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.
Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7:95.
Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang X-F, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010;28:17–28.
Hu Y-Y, Zheng M-H, Cheng G, Li L, Liang L, Gao F, et al. Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer. 2011;11:82.
Bayin NS, Frenster JD, Sen R, Si S, Modrek AS, Galifianakis N, et al. Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. Oncotarget. 2017;8:64932–53.
Ding D, Lim KS, Eberhart CG. Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres. Acta Neuropathol Commun. 2014;2:31.
Alvarez-Trotta A, Guerrant W, Astudillo L, Lahiry M, Diluvio G, Shersher E. et al. Pharmacological disruption of the Notch1 transcriptional complex inhibits tumor growth by selectively targeting cancer stem cells. Cancer Res. 2021;81:3347–57.
Noisa P, Lund C, Kanduri K, Lund R, Lähdesmäki H, Lahesmaa R, et al. Notch signaling regulates the differentiation of neural crest from human pluripotent stem cells. J Cell Sci. 2014;127:2083–94.
Teodorczyk M, Schmidt MHH. Notching on cancer’s door: Notch signaling in brain tumors. Front Oncol. 2015;4:341.
Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL, et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res. 2009;69:431–9.
Tanigawa S, Fujita M, Moyama C, Ando S, Ii H, Kojima Y, et al. Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model. Cancer Gene Ther. 2021;28:1339–52.
Moyama C, Fujita M, Ando S, Taniguchi K, Ii H, Tanigawa S, et al. Stat5b inhibition blocks proliferation and tumorigenicity of glioblastoma stem cells derived from a de novo murine brain cancer model. Am J Cancer Res. 2022;12:1129–42.
Moyama C, Fujita M, Okamoto H, Ii H, Nakata S. Myb repression mediates Stat5b-knockdown-induced apoptosis and inhibits proliferation of glioblastoma stem cells. Cancer Genomics Proteom. 2023;20:195–202.
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014;7:ra121.
Yu X, Zhan X, D’Costa J, Tanavde VM, Ye Z, Peng T, et al. Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther. 2003;7:827–38.
Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, Evelo CT, et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 2012;40:D1301–7.
Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65:2353–63.
Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002;8:979–86.
Mittal S, Sharma A, Balaji SA, Gowda MC, Dighe RR, Kumar RV, et al. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers. Mol Cancer Ther. 2014;13:3198–209.
Kumar D, Kumar S, Gorain M, Tomar D, Patil HS, Radharani NNV, et al. Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis. J Invest Dermatol. 2016;136:2462–74.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41417-024-00835-y